Abstract
Introduction
This double-blind, placebo-controlled study investigated the efficacy and safety of intramuscular (IM) aripiprazole and IM haloperidol for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder.

Materials and methods
Four-hundred and forty-eight patients were randomized (2:2:1 ratio) to IM aripiprazole 9.75 mg, IM haloperidol 6.5 mg, or IM placebo. Patients could receive up to three injections over the first 24 h, with second and third injections administered ≥2 and ≥4 h, respectively, after the first if deemed clinically necessary. Primary efficacy measure was mean change in Positive and Negative Syndrome Scale Excited Component (PEC) score from baseline to 2 h.

Results
Mean improvement in PEC at 2 h was significantly greater for IM aripiprazole (−7.27) vs placebo (−4.78; p<0.001); IM aripiprazole was noninferior to IM haloperidol (−7.75) on PEC. All secondary efficacy measures showed significantly greater improvements at 2 h for IM aripiprazole and IM haloperidol over placebo. Mean number of injections/patient and percentage of patients requiring benzodiazepines were significantly lower for IM aripiprazole vs placebo (p<0.01). IM aripiprazole was well tolerated. Extrapyramidal symptom-related adverse events were similar for aripiprazole (1.7%) and placebo (2.3%) and lower than with haloperidol (12.6%).

Conclusion
These results show that IM aripiprazole is an effective treatment, comparable to IM haloperidol, and well-tolerated for acute agitation in patients with schizophrenia.

Keywords
Acute agitation Intramuscular antipsychotic therapy Intramuscular aripiprazole Intramuscular haloperidol Efficacy Safety 
Joint first authorship for authors Raisa Andrezina and Richard Josiassen.

This is a preview of subscription content, log in to check access.
Notes
Acknowledgments
We would like to thank all of the principal investigators who participated in this study: Mocrane Abbar, M.D. (Hospital Caremeau Service de Psychiatrie, Nimes, France); Jose Alvarez, M.D. (Comprehensive Neurosciences of Melbourne, Melbourne, FL, USA); Professor Raisa Andrezina (Department of Psychiatry, Riga Mental Health Care Centre, Riga, Latvia); Mohammed Abdul Bari, M.D. (Synergy Research Center, San Diego, CA, USA); Louise Beckett, M.D. (IPS Research Company, Oklahoma City, OK, USA); Miguel Bernardo-Arroyo, M.D. (Hospital Clinic Servicio de Psiquiatria, Barcelona, Spain); Daniel Bonnaffoux, M.D. (CHS du Jura, Dole, Cedex, France); Jeffrey Borenstein, M.D. (The Holliswood Hospital, Comprehensive Neuroscience Inc., Holliswood, NY, USA); Ronald Brenner, M.D. (Neurobehavioral Research, Lawrence, NY, USA); David W. Brown, M.D. (Community Clinical Research Inc., Austin, TX, USA); Richard M. Bunt, M.D. (MedPsych Specialists, Decatur, GA, USA); Osvaldo Caro, M.D. (First Hospital Panamericano, Unidad, Ponce, Puerto Rico); James C.Y. Chou, M.D. (New York University School of Medicine, Bellevue Hospital Center, NY, USA); Wlodzimierz Chrzanowski, M.D. (Samodzielny Publicczny Zaklad, Psychiatrycznej Opieki Zdrowotnej, Choroszcz K/Bialegostoku, Poland); Daniel Dassa, M.D. (Hospital Timone Adultes, Marseille, Cedex, France); Thierry Della, M.D. (Centre Hospitalier des Pyrenees, SAAU, Pau, France); Ivan Drabek, M.D. (Psychiatricka Lecebna Opava, Opava, Czech Republic); Katrin Eino, M.D. (Department of Psychiatry, North Estonia Regional Hospital, Tallinn, Estonia); Larry Ereshefsky, Pharm.D. (California Clinical Trials Medical Group, Glendale, CA, USA); David Howard Flaherty, D.O. (Segal Institute for Clinical Research, North Miami, FL, USA); Vera Pavo Filakovic, M.D. (Clinical Hospital Osijek, Psychiatric Clinic, Osijek, Croatia); Folnegovic-Smalc, M.D., Ph.D. (Psychiatric Hospital Vrapce, Zagreb, Croatia); Franco Garonna, M.D. (Azienda Sanitaria Ulss 3, Reparto Di Psichiatria Ospedale Civile, Bassano Del Grappa, Italy); Ramanath Gopalan, M.D. (Comprehensive Neurosciences of Northern Virginia, Falls Church, VA, USA); Sanjay Gupta, M.D. (Global Research and Consulting, Olean, NY, USA); George A.D. Hart, M.B., C.H.B. (Tara Hospital, Hurlingham Gauteng, South Africa); Jaromir Hons, M.D. (University Hospital Clinic of Psychiatry, Hradec Kralove, Czech Republic); Kadri Jaanson, M.D. (South Estonia Hospital, Psychiatry, Meegomae, Vorumaa, Estonia); Richard Jaffe, M.D. (Belmont Center for Comprehensive Treatment, Philadelphia, PA, USA); Jiri Janatka, M.D. (Central Military Hospital Clinic of Psychiatry, Prague, Czech Republic); Richard Josiassen, Ph.D. (Arthur P. Noyes Research Foundation, Norristown, PA, USA); Mary Ann Knesevich, M.D. (University Hills Clinical Research, Irving, TX, USA); Chandra S. Krishnasastry, M.D. (Clinical Research Services at Tennessee Christian Medical Center, Madison, TN, USA); Gunnar Larson, M.D. (C.C.R.I. Zablocki-Milwaukee VAMC, Milwaukee, WI, USA); Bum Soo Lee, M.D. (Anaheim Research Center, LLC, Anaheim, CA, USA); Michael Lesem, M.D. (Claghorn-Lesem Research Clinic, LLC, Bellaire, TX, USA); Michael T. Levy, M.D. (Behavioral Medical Research of Staten Island, Staten Island, NY, USA); Keh-Ming Lin, M.D., M.P.H. (Harbor UCLA Research and Education Institute, South Torrance, CA, USA); David E. Linden, M.D. (Linden Research Consultants, LLC, Oklahoma City, OK, USA); Adam Lowy, M.D. (Comprehensive Neuroscience Inc., Psychiatric Institute of Washington, Washington, DC, USA); Raymond Manning, M.D. (California Neuropsychopharmacology Research Institute–Los Angeles, LLC, Pico Rivera, CA, USA); David M. Marks, M.D. (Optimum Health Services, La Mesa, CA, USA); Denis Mee-Lee, M.D. (Hawaii Clinical Research Center, Honolulu, HI, USA); Ricky S. Mofsen, D.O. (Clinical Research Inc., St. Louis, MO, USA); Pavel Mohr, M.D., Ph.D. (Psychiatricke Centrum Praha, Prague, Czech Republic); Ljiljana Moro, M.D. (Clinical Hospital Rijeka, Psychiatric Clinic, Rijeka, Croatia); Izabela Niewiadomska-Marko, M.D. (Szpital IM. Jana Pawla II, Oddzial Psychiatrii, Nowy Targ, Poland); Anand K. Pandurangi, M.D. (Medical College of Virginia, Richmond, VA, USA); Michael Plopper, M.D. (Sharp Mesa Vista Hospital, San Diego, CA, USA); Pauline S. Powers, M.D. (Department of Psychiatry and Behavioral Medicine, University of South Florida, Tampa, FL, USA); Sohail Punjwani, M.D. (Segal Institute for Clinical Research, North Miami, FL, USA); Ants Puusild, M.D. (Parnu Hospital, Department of Psychiatry, Parnu, Estonia); Jiri Raboch, M.D. (General University Hospital Clinic of Psychiatry, Prague, Czech Republic); Joachim D. Raese, M.D. (Behavioral Health 2000, LLC, Riverside, CA, USA); Rakesh Ranjan, M.D. (Rakesh Ranjan, M.D., and Associates Inc., Lyndhurst, OH, USA); Paulis Revelis, M.D. (Jelgava Psychiatry Hospital, Jelgava, Latvia); Vitalijs Rodins, M.D. (Department of Psychiatry, Strenci Psychiatry Hospital, Strenci, Latvia); David Sack, M.D. (Comprehensive Neuroscience Inc., Cerritos, CA, USA); Scott Daniel Segal, M.D. (Segal Institute for Clinical Research, North Miami, FL, USA); Anantha Shekhar, M.D., Ph.D. (Indiana University Adult Psychiatry, Indianapolis, IN, USA); Michael Smith, M.D. (Harbor UCLA Research and Education Institute, South Torrance, CA, USA); Richard M. Steinbook, M.D. (Department of Psychiatry, University of Miami School of Medicine, Miami, FL, USA); Jaroslaw Strzelec, M.D. (NZOZ Wolmed, Dubie GM. Szczercow, Dubie, Poland); Jaromir Svestka, M.D. (University Hospital Clinic of Psychiatry, Brno-Bohunice, Czech Republic); Tram K. Tran-Johnson, Pharm.D., Psy.D. (California Neuropsychopharmacology Clinical Research Institute–San Diego, LLC, San Diego, CA, USA); Madeleine M. Valencerina, M.D. (Neogenics Clinical Trials, La Palma, CA, USA); Nadine Wertenschlag, M.D. (Etablissement Public de Sante Alsace, Nord Service du Dr. Brunner, Brumath, Cedex, France); Georges Zaykine, M.D. (Clinique Sainte-Therese, Narbonne, France); Dan L. Zimbroff, M.D. (Pacific Clinical Research Medical Group, Upland, CA, USA).

This study was supported by Bristol-Myers Squibb Company (Princeton, NJ) and Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan).

References
ADA/APA/AACE/NAASO (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Diabetes Care 27:596–601
CrossRefGoogle Scholar
APA (1994) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th edn. American Psychiatric Association, Washington, DC
Google Scholar
Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676
PubMedCrossRefGoogle Scholar
Battaglia J, Lindborg SR, Alaka K, Meehan K, Wright P (2003) Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med 21:192–198
PubMedCrossRefGoogle Scholar
Beuzen J-N, Schirr K, Pans M, Hagens P, Kostic D, Carson W, Auby P (2006) Effectiveness of aripiprazole in a naturalistic setting: a European multicenter study. Schizophr Res 81 (Suppl 3):39
Google Scholar
Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, Taylor CC, Palmer R, Dossenbach M, Kiesler G, Brook S, Wright P (2002) A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 59:441–448
PubMedCrossRefGoogle Scholar
Brook S, Walden J, Benattia I, Siu CO, Romano SJ (2005) Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl) 178:514–523
CrossRefGoogle Scholar
Corrigan JD, Bogner JA (1994) Factor structure of the Agitated Behavior Scale. J Clin Exp Neuropsychol 16:386–392
PubMedCrossRefGoogle Scholar
Currier GW, Trenton A (2002) Pharmacological treatment of psychotic agitation. CNS Drugs 16:219–228
PubMedCrossRefGoogle Scholar
Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP (2001) Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 155:128–134
CrossRefGoogle Scholar
Guy W (1976) Clinical Global Impressions (CGI) ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare Publication (ADM) 76–338. National Institute of Mental Health, Rockville, MD, pp 218–222
Google Scholar
Hassaballa HA, Balk RA (2003) Torsade de pointes associated with the administration of intravenous haloperidol: a review of the literature and practical guidelines for use. Expert Opin Drug Saf 2:543–547
PubMedGoogle Scholar
Hofer A, Kemmler G, Eder U, Honeder M, Hummer M, Fleischhacker WW (2002) Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry 63:49–53
PubMedGoogle Scholar
Hughes DH, Kleespies PM (2003) Treating aggression in the psychiatric emergency service. J Clin Psychiatry 64:10–15
PubMedGoogle Scholar
Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63:763–771
PubMedGoogle Scholar
Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T (2003) Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 6:325–337
PubMedCrossRefGoogle Scholar
Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP (2001) Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 62:12–18
PubMedCrossRefGoogle Scholar
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223
PubMedCrossRefGoogle Scholar
Lindenmayer JP, Brown E, Baker RW, Schuh LM, Shao L, Tohen M, Ahmed S, Stauffer VL (2004) An excitement subscale of the Positive and Negative Syndrome Scale. Schizophr Res 68:331–337
PubMedCrossRefGoogle Scholar
Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T (2003) Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61:123–136
PubMedCrossRefGoogle Scholar
McCreadie RG (1996) Managing the first episode of schizophrenia: the role of new therapies. Eur Neuropsychopharmacol 6:S3–S5
PubMedCrossRefGoogle Scholar
McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH (2004) A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 65:47–56
PubMedGoogle Scholar
Melkersson K, Dahl ML (2004) Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 64:701–723
PubMedCrossRefGoogle Scholar
Modell S, Daniel D, Stock E, Wilber R, Marcus R, Carson W, Manos G (2004) Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. Int J Neuropsychopharmacol 7(Suppl 1):S417
Google Scholar
Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19:1–93
PubMedCrossRefGoogle Scholar
Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG (2003) Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 64:1048–1056
PubMedCrossRefGoogle Scholar
Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681–690
PubMedCrossRefGoogle Scholar
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59:22–33; quiz 34–57
PubMedGoogle Scholar
Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11–19
PubMedCrossRefGoogle Scholar
Stimmel GL (1996) Benzodiazepines in schizophrenia. Pharmacotherapy 16:148S–151S; discussion 166S–168S
PubMedGoogle Scholar
Tandon R, Marcus RN, Stock EG, Riera LC, Kostic D, Pans M, McQuade RD, Nyilas M, Iwamoto T, Crandall DT (2006) A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res 84:77–89
PubMedCrossRefGoogle Scholar
Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, Saunders JC, Krueger J, Bradley P, San L, Bernardo M, Reinstein M, Breier A (2001) Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 158:1149–1151
PubMedCrossRefGoogle Scholar